KODIAK SCIENCES INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent
KODIAK SCIENCES INC. (KOD) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent of -1.90% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2026-03-31
- KODIAK SCIENCES INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2025 was -1.90%.
- KODIAK SCIENCES INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2024 was -5.10%.
- KODIAK SCIENCES INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2023 was -4.10%.
- KODIAK SCIENCES INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2022 was -3.90%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent 12 month |
|---|---|
| 2025-12-31 | -1.90% 10-K · filed 2026-03-31 |
| 2024-12-31 | -5.10% 10-K · filed 2026-03-31 |
| 2023-12-31 | -4.10% 10-K · filed 2026-03-31 |
| 2022-12-31 | -3.90% 10-K · filed 2025-03-27 |
| 2021-12-31 | -1.20% 10-K · filed 2024-03-28 |
| 2020-12-31 | 6.70% 10-K · filed 2023-03-28 |
| 2019-12-31 | 7.70% 10-K · filed 2022-03-01 |
| 2018-12-31 | -0.60% 10-K · filed 2021-03-01 |
| 2017-12-31 | -0.30% 10-K · filed 2020-03-16 |
| 2016-12-31 | -0.20% 10-K · filed 2019-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |